P
PHARVARIS BV
NASDAQ: PHVS (Pharvaris N.V.)
Last update: 9 hours ago30.02
0.00 (0.00%)
| Previous Close | 30.02 |
| Open | 30.06 |
| Volume | 538,117 |
| Avg. Volume (3M) | 203,047 |
| Market Cap | 1,963,542,912 |
| Price / Book | 6.07 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2026 |
| Diluted EPS (TTM) | -3.27 |
| Total Debt/Equity (MRQ) | 0.33% |
| Current Ratio (MRQ) | 11.10 |
| Operating Cash Flow (TTM) | -134.37 M |
| Levered Free Cash Flow (TTM) | -79.65 M |
| Return on Assets (TTM) | -31.88% |
| Return on Equity (TTM) | -52.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Pharvaris N.V. | Bullish | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | 5.0 |
| Insider Activity | -5.0 |
| Price Volatility | -1.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 0.80 |
|
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 6.25% |
| % Held by Institutions | 89.49% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| General Atlantic, L.P. | 31 Dec 2025 | 8,031,252 |
| Foresite Capital Management Iv, Llc | 31 Dec 2025 | 4,778,581 |
| Venbio Partners Llc | 31 Dec 2025 | 4,639,304 |
| Viking Global Investors Lp | 31 Dec 2025 | 3,653,310 |
| Eqt Fund Management S.A R.L. | 31 Dec 2025 | 3,424,609 |
| Deerfield Management Company, L.P. | 31 Dec 2025 | 3,126,042 |
| Bain Capital Life Sciences Investors, Llc | 31 Dec 2025 | 2,802,081 |
| Novo Holdings A/S | 31 Dec 2025 | 1,750,000 |
| Saturn V Capital Management Lp | 31 Dec 2025 | 1,140,033 |
| Cormorant Asset Management, Lp | 31 Dec 2025 | 1,083,000 |
| 5Am Venture Management, Llc | 31 Dec 2025 | 797,600 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (HC Wainwright & Co., 99.87%) | Buy |
| Median | 56.00 (86.54%) | |
| Low | 52.00 (RBC Capital, 73.22%) | Buy |
| Average | 56.00 (86.54%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 26.64 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 09 Mar 2026 | 52.00 (73.22%) | Buy | 26.51 |
| HC Wainwright & Co. | 03 Mar 2026 | 60.00 (99.87%) | Buy | 26.78 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LESAGE ANNE | - | 29.50 | -59,300 | -1,819,718 |
| LU PENG | - | 29.54 | -25,834 | -789,544 |
| SCHIKAN JOHANNES GERARDUS CHRISTIAAN PETRUS | - | 29.54 | -40,000 | -1,228,719 |
| Aggregate Net Quantity | -125,134 | |||
| Aggregate Net Value ($) | -3,837,981 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 29.52 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LU PENG | Officer | 30 Apr 2026 | Automatic sell (-) | 15,000 | 31.01 | 465,150 |
| LU PENG | Officer | 30 Apr 2026 | Option execute | 15,000 | - | - |
| LESAGE ANNE | Officer | 30 Apr 2026 | Automatic sell (-) | 21,700 | 31.01 | 672,917 |
| LESAGE ANNE | Officer | 30 Apr 2026 | Automatic sell (-) | 19,200 | 31.01 | 595,392 |
| LESAGE ANNE | Officer | 30 Apr 2026 | Option execute | 21,700 | - | - |
| SCHIKAN JOHANNES GERARDUS CHRISTIAAN PETRUS | Director | 30 Apr 2026 | Automatic sell (-) | 29,070 | 31.01 | 901,461 |
| LU PENG | Officer | 29 Apr 2026 | Automatic sell (-) | 3,733 | 29.83 | 111,355 |
| LU PENG | Officer | 29 Apr 2026 | Option execute | 3,733 | - | - |
| LESAGE ANNE | Officer | 29 Apr 2026 | Automatic sell (-) | 3,700 | 29.83 | 110,371 |
| LESAGE ANNE | Officer | 29 Apr 2026 | Option execute | 3,700 | - | - |
| SCHIKAN JOHANNES GERARDUS CHRISTIAAN PETRUS | Director | 29 Apr 2026 | Automatic sell (-) | 3,830 | 29.83 | 114,249 |
| LU PENG | Officer | 23 Apr 2026 | Automatic sell (-) | 100 | 27.29 | 2,729 |
| LU PENG | Officer | 23 Apr 2026 | Option execute | 100 | - | - |
| LESAGE ANNE | Officer | 23 Apr 2026 | Sell (-) | 100 | 27.29 | 2,729 |
| LESAGE ANNE | Officer | 23 Apr 2026 | Automatic sell (-) | 100 | 27.29 | 2,729 |
| LESAGE ANNE | Officer | 23 Apr 2026 | Option execute | 100 | - | - |
| SCHIKAN JOHANNES GERARDUS CHRISTIAAN PETRUS | Director | 23 Apr 2026 | Automatic sell (-) | 100 | 27.29 | 2,729 |
| LU PENG | Officer | 22 Apr 2026 | Automatic sell (-) | 7,001 | 30.04 | 210,310 |
| LU PENG | Officer | 22 Apr 2026 | Option execute | 7,001 | - | - |
| LESAGE ANNE | Officer | 22 Apr 2026 | Automatic sell (-) | 7,500 | 30.04 | 225,300 |
| LESAGE ANNE | Officer | 22 Apr 2026 | Sell (-) | 7,000 | 30.04 | 210,280 |
| LESAGE ANNE | Officer | 22 Apr 2026 | Option execute | 7,500 | - | - |
| SCHIKAN JOHANNES GERARDUS CHRISTIAAN PETRUS | Director | 22 Apr 2026 | Automatic sell (-) | 7,000 | 30.04 | 210,280 |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |